Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory sinonasal disease characterized by nasal polyps and symptoms such as congestion, rhinorrhea, reduced smell, and facial pressure. It often has recurrent disease burden and can require long-term medical and surgical management.
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.
The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07520162 |
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab |
RECRUITING | PHASE3 |
| NCT07484230 |
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps |
NOT_YET_RECRUITING | PHASE3 |
| NCT07446738 |
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients |
RECRUITING | |
| NCT07424144 |
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT07420257 |
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07316959 |
Efficacy of Long-Term Low Dose Macrolide Therapy in Preventing Early Recurrence of Nasal Polyps After Endoscopic Sinus Surgery |
COMPLETED | NA |
| NCT07187583 |
Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps |
RECRUITING | PHASE4 |
| NCT07184684 |
Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis (CRS). |
RECRUITING | PHASE2/PHASE3 |
| NCT07132827 |
Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps |
RECRUITING | PHASE3 |
| NCT06914908 |
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study |
ENROLLING_BY_INVITATION | PHASE2 |
